Immune globulin - Biotest Pharmaceuticals

Drug Profile

Immune globulin - Biotest Pharmaceuticals

Alternative Names: BT-595; Human normal immunoglobulin - Biotest; Pentaglobin

Latest Information Update: 10 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Biotest Pharmaceuticals
  • Developer Biotest Pharmaceuticals; RWTH Aachen University
  • Class Antidementias; Antivirals; Immunoglobulins; Immunoproteins; Serum globulins
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Idiopathic thrombocytopenic purpura; Immunodeficiency disorders
  • Phase II Sepsis; Septic shock

Most Recent Events

  • 11 Apr 2018 Gruppo Italiano Trapianto di Midollo Osseo plans the PENTALLO phase II trial for Septic Shock in Italy , (NCT03494959)
  • 02 Oct 2017 Phase-II clinical trials in Sepsis (In adults, In the elderly) in Germany (IV)
  • 02 Oct 2017 Phase-II clinical trials in Septic shock (In adults, In the elderly) in Germany (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top